Health & Fitness
Health and Fitness
Health and Fitness
Wed, January 14, 2009
Tue, January 13, 2009 Vitro Announces Application of its Stem Cell Technology to Cancer Research & Treatment
GOLDEN, Colo.--([ BUSINESS WIRE ])--Vitro Diagnostics, Inc. (OTCBB: VODG), dba Vitro Biopharma, announced advances in its adult stem cell research indicating application of its technology and stem cell lines to cancer research and treatment. Cancer stem cells may generate solid tumors in various forms of cancer including those with poor prognosis including malignancies of the pancreas, lung and brain. Cancer stem cells may also be resistant to chemotherapy and radiation causing recurrences and metastasis of cancer following standard therapy. Additional research shows that other stem cells, including a type of adult stem cell known as mesenchymal stem cells (MSC) that Vitro is presently developing, migrate to cancer stem cells and may be used to carry toxic agents to selectively eradicate cancer stem cells thereby providing novel cellular therapy specifically targeted to cancer-causing cells.
Vitro's stem cell research is now centered on the development of human MSCs for diabetes research, drug discovery and treatment. Recent research by the Company also indicates potential application of its MSC lines to cancer research that may lead to novel cell therapy for cancer. The Company has filed for patent protection of its novel technology and compositions related to cancer research and therapy. Furthermore, the Company plans to pursue development of stem cell products for use in cancer stem cell research including methods to target the selective eradication of cancer stem cells. The Company hopes to have products available for cancer research use in the near future.
Dr. Jim Musick, Vitro's President and CEO, said, "We are pleased to announce the application of our technology to cancer research and therapy. This will allow additional opportunities for short-term revenue generation and the potential development of novel therapies for cancer. This provides a fundamental expansion of our business prospects and multiple opportunities for product and revenue growth. Also, in concert with the goals of the new administration, we hope to contribute advances that reduce costs of health care especially for diabetes and cancer, chronic conditions that result in significant burdens in terms of costs and associated impacts to society, families and patients. We also hope to advance the medical applications of stem cell technology, especially focusing on the value of adult stem cells."
About Vitro Diagnostics, Inc.
Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCBB: VODG; [ http://www.vitrodiag.com ]) is committed to "Harnessing the Power of Cells" and owns proprietary technology, cell lines and related products with potential application to treatment of cancer, diabetes and infertility. Vitro recently established a new, high-tech and regulatory-compliant manufacturing, R&D and corporate facility in Golden, Colorado. The current focus is development and commercialization of adult stem cell lines for use in diabetes research, drug development and therapy. Vitro's stem cell technology also has application to cancer stem cell research for development of targeted cell therapies for recalcitrant cancers including malignancies of the pancreas, lung and brain.
Safe Harbor Statement
Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written, may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and include, without limitation, statements regarding the Company's plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company's products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company's filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.
